Evidence suggest that basal-bolus therapy for patients with type 1 diabetes using IGlar has been associated with a reduced number of daily injections [2, 3], a reduced frequency of hypoglycaemia [3–7], a reduced variability of fasting plasma glucose (FPG) concentration [2] and lower FPG and HbA1c levels [4, 6–9] relative to NPH insulin, which is indicative of the benefits of IGlar for such therapy. This evidence concerns the gene INS and Hypoglycemia.